 |
|
|
| |
Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin Reduces Treatment Duration in Previously Untreated and Previous-Treatment-Failure Patients With HCV Genotype 1
|
| |
| |
Reported by Jules Levin EASL 2011 Berlin Germany March 30-Apr 2
M.P. Manns1*, F. Poordad2, B.R. Bacon3, S. Bruno4, R. Esteban5, M. Silva6, M. Buti5, M. Burroughs7, V. Sniukiene7, N. Boparai7, C.A. Brass7, J.K. Albrecht7, J.-P. Bronowicki8
1Medical School of Hannover, Hannover, Germany, 2Cedars-Sinai Medical Center, Los Angeles, CA, USA, 3Saint Louis University School of Medicine, Saint Louis, MO, USA, 4A.O. Fatebenefratelli e Oftalmico, Milan, Italy, 5Vall d'Hebron University Hospital, Barcelona, Spain, 6Hospital Universitario Austral, Pilar, Argentina, 7Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 8University Henri Poincare of Nancy, Vandoeuvre-lès-Nancy, France. *manns.michael@mh-hannover.de
AUTHOR CONCLUSIONS
· Addition of BOC to P/R standard-of-care results in significant increases in SVR in both naïve and treatment failure patients
· In previously untreated patients, 57% of patients had undetectable HCV RNA at week 8 (early responders) and 88% achieved SVR with a total treatment duration of 28 weeks.
- Among the 44% of BOC recipients who attained undetectable HCV-RNA at weeks 8 through 24, a total treatment duration of 28 weeks in the BOC RGT arm resulted in 96% SVR
· In previous treatment failure patients (ie, nonresponders/relapsers), 46% of patients had undetectable HCV RNA at week 8 (early responders) and 86% achieved SVR with a total treatment duration of 32 weeks.
· Early responders who received shorter therapy in the BOC RGT arm had similar SVR rates as the early responders who received longer therapy in the BOC/PR48 arm
· Based on the lower exposure rate offered by RGT (see poster 449 for a detailed description of safety in the key studies), and similar efficacy, RGT may be the preferred approach to treating both previously untreated and previous treatment failure patients.
|
| |
|
|
|
|
|
